These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39168901)

  • 1. Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer.
    Pant S; Cho BC; Kyriakopoulos CE; Spira A; Tannir N; Werner TL; Yan X; Neuteboom S; Chao R; Goel S
    Invest New Drugs; 2024 Oct; 42(5):547-558. PubMed ID: 39168901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study.
    Bazhenova L; Kim DW; Cho BC; Goel S; Heist R; Werner TL; Eaton KD; Wang JS; Pant S; Adkins DR; Blakely CM; Yan X; Neuteboom S; Christensen JG; Chao R; Bauer T
    Future Oncol; 2024 Dec; 20(39):3213-3227. PubMed ID: 39513224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.
    Agarwal N; Brugarolas J; Ghatalia P; George S; Haanen JB; Gurney H; Ravilla R; Van der Veldt A; Beuselinck B; Pokataev I; Suelmann BBM; Tuthill MH; Vaena D; Zagouri F; Wu J; Perini RF; Liu Y; Merchan J; Atkins MB
    Ann Oncol; 2024 Dec; 35(12):1148-1156. PubMed ID: 39233312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S
    Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma.
    Cai L; Roos J; Miranda PAP; Liljas B; Rule S; Wang M
    J Med Econ; 2024; 27(1):1552-1557. PubMed ID: 39461001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT.
    Crawley E; Anderson E; Cochrane M; Shirkey BA; Parslow R; Hollingworth W; Mills N; Gaunt D; Treneman-Evans G; Rai M; Macleod J; Kessler D; Pitts K; Cooper S; Loades M; Annaw A; Stallard P; Knoop H; Van de Putte E; Nijhof S; Bleijenberg G; Metcalfe C
    Health Technol Assess; 2024 Oct; 28(70):1-134. PubMed ID: 39485730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Sachdeva A; Jones C; Hoyle A; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Gilson C; Rush H; Abdel-Aty H; Amos CL; Murphy C; Chowdhury S; Malik Z; Russell JM; Parkar N; Pugh C; Diaz-Montana C; Pezaro C; Grant W; Saxby H; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzouebi M; Parikh O; Robinson A; Montazeri AH; Wylie J; Zarkar A; Cathomas R; Brown MD; Jain Y; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet Oncol; 2023 May; 24(5):443-456. PubMed ID: 37142371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study.
    Zinzani PL; Izutsu K; Mehta-Shah N; Barta SK; Ishitsuka K; Córdoba R; Kusumoto S; Bachy E; Cwynarski K; Gritti G; Prica A; Jacobsen E; Feldman T; Guillermin Y; Ennishi D; Yoon DH; Domenech ED; Zain J; Wang J; Kim JS; Poel MV; Jin J; Wu S; Chen Y; Moriyama T; Inoue A; Nakajima K; Horwitz SM
    Lancet Oncol; 2024 Dec; 25(12):1602-1613. PubMed ID: 39486433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world data on the efficacy and safety of hedgehog pathway inhibitors in patients with basal cell carcinoma: Experience of a tertiary Australian centre.
    Truong K; Peera M; Liu R; Wijaya M; Jones-Caballero M; Araujo RR; Fernandez-Penas P
    Australas J Dermatol; 2024 Dec; 65(8):e248-e254. PubMed ID: 39451045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.
    Leary A; Estévez-García P; Sabatier R; Ray-Coquard I; Romeo M; Barretina-Ginesta P; Gil-Martin M; Garralda E; Bosch-Barrera J; Morán T; Martin-Martorell P; Nadal E; Gascón P; Rodon J; Lizcano JM; Muñoz-Guardiola P; Fierro-Durán G; Pedrós-Gámez O; Pérez-Montoyo H; Yeste-Velasco M; Cortal M; Pérez-Campos A; Alfon J; Domenech C; Pérez-Fidalgo A; Oaknin A
    BMC Cancer; 2024 Jul; 24(1):876. PubMed ID: 39039449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer.
    Heath EI; Chen W; Choi JE; Dobson K; Smith M; Maj T; Kryczek I; Zou W; Chinnaiyan AM; Qiao Y
    Invest New Drugs; 2024 Dec; 42(6):675-684. PubMed ID: 39503807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of abstinence-based and harm reduction-based interventions in reducing problematic substance use in adults who are experiencing homelessness in high income countries: A systematic review and meta-analysis: A systematic review.
    O'Leary C; Ralphs R; Stevenson J; Smith A; Harrison J; Kiss Z; Armitage H
    Campbell Syst Rev; 2024 Jun; 20(2):e1396. PubMed ID: 38645303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.